| Primary information |
|---|
| ID | 1002 |
| Peptide Name | Cyclosporin A (CsA) |
| Sequence | cyclo[Abu-Sar-N(Me)Leu-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)] |
| Length | 11 |
| Chirality | Mix |
| N-terminal Modification | None |
| C-terminal Modification | None |
| Chemical Modification | Bmt = butenyl-methyl-threonine, Abu = L-alpha-aminobutyric acid, Sar = sarcosine, N(Me) = Amino acid is N-methylated |
| Linear/ Cyclic | Cyclic |
| Nature | Natural |
| Source of Origin | Fungus |
| Target | Reduction of the IL-2 surface receptor CD25 expression (76%±11 after 24 hrs and 62%±7.3 after 36 hrs), also reduces TNF-α expression (23%±1.8) |
| Mechanism of Action | Inhibits the production of IL-2 |
| In vitro/In vivo | In vitro |
| Cell Line | Human peripheral Lymphocytes and purified T cells |
| Inhibition Concentartion | NA |
| In vivo Model | None |
| Assay | Cell Proliferation assay, Ca2+ release assay, Cytokines release assay |
| Lethal Dose | NA |
| Combination Therapy | NA |
| Pubmed ID | 23840803 |
| Year of Publication | 2013 |
| 3-D Structure | NA |
